ATXN3 (Ataxin-3) is a polyglutamine disease protein associated with Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease. ATXN3 is a deubiquitinating enzyme that plays critical roles in protein quality control, transcriptional regulation, and DNA repair. The pathogenic expansion of CAG repeats leads to protein aggregation and neurodegeneration.
ATXN3 encodes a deubiquitinating enzyme (DUB) of the Josephin family that functions in protein quality control. The protein contains a catalytic Josephin domain at the N-terminus and a polyglutamine (polyQ) tract that undergoes pathological expansion in SCA3/MJD [1][2].
Under normal conditions, ATXN3:
In disease, expanded polyQ tracts cause:
ATXN3 encodes a deubiquitinating enzyme that cleaves ubiquitin chains from substrate proteins. The protein is widely expressed with high levels in neurons, particularly in the cerebellum, brainstem, and spinal cord.
ATXN3 is a cysteine protease with unique substrate specificity [1][4]:
| Activity | Function |
|---|---|
| DUB activity | Cleaves Ub linkages (K48, K63) |
| Josephin domain | Catalytic protease domain |
| PolyQ tract | Regulatory, pathogenic expansion |
SCA3, also known as Machado-Joseph Disease, is the most common dominant ataxia worldwide [3][6].
Genetics:
Pathogenesis:
| Mechanism | Description |
|---|---|
| PolyQ aggregation | Expanded ATXN3 forms insoluble aggregates |
| Transcriptional dysregulation | Sequestration of transcription factors |
| Mitochondrial dysfunction | Energy metabolism impairment |
| Autophagy impairment | Lysosomal clearance defects |
| Neuroinflammation | Glial activation, cytokine release [7] |
Clinical Features:
ATXN3 contains several functional domains [1][4]:
| Domain | Position | Function |
|---|---|---|
| Josephin domain | N-terminus (1-182) | Catalytic DUB activity |
| UIM 1-3 | Middle region | Ubiquitin binding |
| PolyQ tract | Variable | Pathological expansion |
| C-terminal region | C-terminus | Protein interactions |
The Josephin domain contains the catalytic triad (Cys178, Asp180, His183) essential for DUB activity [1].
Multiple therapeutic strategies are in development [10][11]:
The study of Atxn3 — Ataxin 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lima M, et al. Spinocerebellar ataxia type 3: a review. J Neurol Sci. 2022;440:120397.
Jardim LB, et al. Phenotype features of Machado-Joseph disease. Neurology. 2001;57(11):1918-1921.
Miller J, et al. Antis oligonucleotide therapy for SCA3. Nat Med. 2020;26(8):1278-1290.
Torres-Odio S, et al. Molecular pathways in SCA3. Mov Disord. 2021;36(8):1754-1767.